Table 3 Multivariate analysis of overall survival (OS) and progression-free survival (PFS) for patients diagnosed with Waldenström macroglobulinemia (WM) with extramedullary involvement (EMWM)

Age ≥65 years

1.41

0.67–2.97

0.367

Race (white)

0.50

0.25–1.00

0.051

IPSSWM (I, II vs III)

1.41

0.90–2.21

0.138

IgM >7000 mg/L

0.42

0.15–1.16

0.094

ALB <3.5 g/dL

2.09

1.07–4.07

0.031

Cytogenetic (abnormal)

1.86

1.09–3.17

0.022

BM involvement

0.99

0.98–1.00

0.080

-

-

-

-

Age ≥65 years

3.13

1.85–5.29

<0.001

Race (white)

0.57

0.32–1.05

0.070

Hb ≤11.5 g/L

1.12

0.65–1.93

0.685

IgM >7000 mg/L

0.49

0.23–1.04

0.064

B symptom–positive

1.25

0.72–2.17

0.428

Cytogenetic (abnormal)

1.78

1.21–2.63

0.003

EM–positive

4.28

2.42–7.55

<0.001

EM–positive

2.06

1.39–3.06

<0.001

PLT <100 × 10⁹/L

1.14

0.63–2.05

0.663

PLT <100 × 10⁹/L

0.98

0.60–1.59

0.935

ALB <3.5 g/dL

2.10

1.24–3.54

0.006

ALB <3.5 g/dL

1.12

0.69–1.80

0.648

LDH >618 IU/L

2.00

0.98–4.06

0.054

LDH >618 IU/L

1.47

0.87–2.51

0.153

β2-MG >3 mg/L

1.36

0.78–2.38

0.277

β2-MG >3 mg/L

1.42

0.92–2.17

0.111